🇺🇸 FDA
Patent

US 8772013

Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells

granted A61KA61K31/337A61K31/704

Quick answer

US patent 8772013 (Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells) held by EnGeneIC Molecular Delivery Pty Ltd expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
EnGeneIC Molecular Delivery Pty Ltd
Grant date
Tue Jul 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/337, A61K31/704, A61K9/0019, A61K9/5068